{{knowledge objective
|Identifiant=OIC-066-17-B
|Item_parent=Diagnose: depressive disorder, anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, adjustment disorder, personality disorder
|Item_parent_short=Diagnose: depressive disorder, anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, adjustment disorder, personality disorder
|Rank=B
|Title=Knowing the indications for pharmacological treatments
|Description=Refer to item 74
|Rubric=Management
|Contributors=El-Hage Wissam
|Order=17}}

An SSRI-type antidepressant for moderate to severe EDC, as first-line treatment, at an effective dose depending on tolerance. Response is assessed after at least 2 weeks of treatment, with a delay in onset of action of several weeks. Discontinuation of an antidepressant after a first CDE is discussed 6-12 months after clinical remission (risk of relapse 6-8 months after stopping the drug) (Item 74).

An antipsychotic should be combined with the antidepressant if psychotic features are present. A benzodiazepine anxiolytic should be combined at the start of treatment in cases of severe anxiety. A hypnotic treatment may be proposed for a limited period (4 weeks) after the introduction of sleep hygiene rules (Item 74).

Monitor the efficacy and tolerability of treatment, the risk of suicide and the risk of manic episodes on antidepressants (Item 74).

In the case of recurrent depressive disorder, antidepressants (molecule and dosage) should be continued after symptomatic remission Â± psychotherapy for a period of 2 years.

Structured psychotherapy is indicated as monotherapy for mild CDD and in combination with antidepressants for moderate to severe CDD. The therapies recommended are cognitive-behavioural and interpersonal therapies (Item 73).